$NWBO
NORTHWEST BIOTHERAPEUTICS INC

2019 Q4 Form 10-K Financial Statement

#000110465921044832 Filed on March 31, 2021

View on sec.gov

Income Statement

Concept 2019 Q4 2019 2018 Q4
Revenue $897.0K $2.410M $412.0K
YoY Change 117.72% 484.95% 1273.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.615M $16.28M $27.02M
YoY Change -86.62% -39.73% 472.35%
% of Gross Profit
Research & Development $4.014M $14.11M $18.15M
YoY Change -77.89% -22.3% 48964.86%
% of Gross Profit
Depreciation & Amortization $5.000K $21.00K $228.0K
YoY Change -97.81% -98.38% -24.0%
% of Gross Profit
Operating Expenses $7.629M $14.11M $45.17M
YoY Change -83.11% -22.3% 121978.38%
Operating Profit -$27.98M
YoY Change -32.55%
Interest Expense $14.71M $2.975M $5.602M
YoY Change 162.58% -69.86% -180.37%
% of Operating Profit
Other Income/Expense, Net $7.167M $0.00
YoY Change 26.02%
Pretax Income $6.545M -$20.81M -$35.79M
YoY Change -118.29% -41.86% 32.57%
Income Tax $0.00
% Of Pretax Income
Net Earnings $6.545M -$20.81M -$35.79M
YoY Change -118.29% -41.86% 32.57%
Net Earnings / Revenue 729.65% -863.57% -8687.86%
Basic Earnings Per Share -$0.04
Diluted Earnings Per Share $10.91K -$0.04 -$81.35K
COMMON SHARES
Basic Shares Outstanding 564.2K 513.4M shares
Diluted Shares Outstanding 564.2K

Balance Sheet

Concept 2019 Q4 2019 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $372.0K $372.0K $22.22M
YoY Change -98.33% -98.33% 18420.0%
Cash & Equivalents $372.0K $372.0K $22.22M
Short-Term Investments
Other Short-Term Assets $2.828M $2.828M $1.574M
YoY Change 79.67% 79.67% 22.02%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.200M $3.200M $23.80M
YoY Change -86.55% -86.55% 1597.43%
LONG-TERM ASSETS
Property, Plant & Equipment $281.0K $6.645M $108.0K
YoY Change 160.19% 6052.78% -99.77%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $798.0K $798.0K $761.0K
YoY Change 4.86% 4.86% 4376.47%
Total Long-Term Assets $7.443M $7.443M $869.0K
YoY Change 756.5% 756.5% -98.17%
TOTAL ASSETS
Total Short-Term Assets $3.200M $3.200M $23.80M
Total Long-Term Assets $7.443M $7.443M $869.0K
Total Assets $10.64M $10.64M $24.67M
YoY Change -56.85% -56.85% -49.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.19M $10.19M $20.09M
YoY Change -49.28% -49.28% 9.21%
Accrued Expenses $395.0K $395.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $6.135M $6.135M $14.81M
YoY Change -58.58% -58.58% -24.43%
Total Short-Term Liabilities $44.20M $44.20M $69.84M
YoY Change -36.72% -36.72% -20.35%
LONG-TERM LIABILITIES
Long-Term Debt $6.588M $6.588M $1.986M
YoY Change 231.72% 231.72% -76.69%
Other Long-Term Liabilities $4.914M $4.914M
YoY Change
Total Long-Term Liabilities $11.50M $11.50M $1.986M
YoY Change 479.15% 479.15% -76.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.20M $44.20M $69.84M
Total Long-Term Liabilities $11.50M $11.50M $1.986M
Total Liabilities $55.70M $55.70M $71.83M
YoY Change -22.45% -22.45% -25.34%
SHAREHOLDERS EQUITY
Retained Earnings -$841.4M -$824.4M
YoY Change 2.06% 4.54%
Common Stock $795.5M $776.3M
YoY Change 2.48% 7.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$45.06M -$45.06M -$48.13M
YoY Change
Total Liabilities & Shareholders Equity $10.64M $10.64M $24.67M
YoY Change -56.85% -56.85% -49.56%

Cashflow Statement

Concept 2019 Q4 2019 2018 Q4
OPERATING ACTIVITIES
Net Income $6.545M -$20.81M -$35.79M
YoY Change -118.29% -41.86% 32.57%
Depreciation, Depletion And Amortization $5.000K $21.00K $228.0K
YoY Change -97.81% -98.38% -24.0%
Cash From Operating Activities -$5.978M -$31.86M -$14.18M
YoY Change -57.84% -7.88% -4.2%
INVESTING ACTIVITIES
Capital Expenditures -$114.0K -$360.0K -$193.0K
YoY Change -40.93% 86.53%
Acquisitions
YoY Change
Other Investing Activities $45.60M
YoY Change
Cash From Investing Activities -$114.0K -$360.0K $45.40M
YoY Change -100.25% -100.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.134M 9.952M -10.82M
YoY Change -147.44% 26.44% -175.72%
NET CHANGE
Cash From Operating Activities -5.978M -31.86M -14.18M
Cash From Investing Activities -114.0K -360.0K 45.40M
Cash From Financing Activities 5.134M 9.952M -10.82M
Net Change In Cash -958.0K -21.85M 20.40M
YoY Change -104.7% -216.94% -4100.59%
FREE CASH FLOW
Cash From Operating Activities -$5.978M -$31.86M -$14.18M
Capital Expenditures -$114.0K -$360.0K -$193.0K
Free Cash Flow -$5.864M -$31.50M -$13.98M
YoY Change -58.07% -8.41% -5.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001072379
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Entity Registrant Name
EntityRegistrantName
NORTHWEST BIOTHERAPEUTICS INC
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
829600000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
614300000
CY2020 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.37
CY2020 nwbo Class Of Warrant Or Right Warrant Term
ClassOfWarrantOrRightWarrantTerm
P2Y
CY2020Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P2Y6M
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
4300000
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-35737
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3306718
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
4800 Montgomery Lane
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 800
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Bethesda
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20814
CY2020 dei City Area Code
CityAreaCode
240
CY2020 dei Local Phone Number
LocalPhoneNumber
497-9024
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2020 dei Trading Symbol
TradingSymbol
NWBO
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
234821000
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
842137013
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9983000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
372000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5528000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2828000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
15511000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
3200000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1040000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
281000
CY2020Q4 nwbo Constructions In Progress Net
ConstructionsInProgressNet
9074000
CY2019Q4 nwbo Constructions In Progress Net
ConstructionsInProgressNet
1685000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4489000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4679000
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1292000
CY2019Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
0
CY2020Q4 us-gaap Goodwill
Goodwill
626000
CY2019Q4 us-gaap Goodwill
Goodwill
0
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
867000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
798000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
17388000
CY2019Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
7443000
CY2020Q4 us-gaap Assets
Assets
32899000
CY2019Q4 us-gaap Assets
Assets
10643000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7380000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6348000
CY2020Q4 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
5363000
CY2019Q4 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
3844000
CY2020Q4 nwbo Convertible Notes Payable Net Current
ConvertibleNotesPayableNetCurrent
3830000
CY2019Q4 nwbo Convertible Notes Payable Net Current
ConvertibleNotesPayableNetCurrent
568000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2437000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5501000
CY2019Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
66000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8275000
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
7261000
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
354972000
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
20213000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
167000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
395000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
382424000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
44196000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8507000
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
6588000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4916000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4914000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
13423000
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
11502000
CY2020Q4 us-gaap Liabilities
Liabilities
395847000
CY2019Q4 us-gaap Liabilities
Liabilities
55698000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1200000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
829600000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
614300000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
830000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
614000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1008665000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
794900000
CY2020Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
79000
CY2019Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
10000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1371216000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-841395000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1148000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-20812000
CY2020 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1532000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8142000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-360000
CY2020 nwbo Proceeds From Issuance Of Capital Stock And Warrants
ProceedsFromIssuanceOfCapitalStockAndWarrants
26814000
CY2019 nwbo Proceeds From Issuance Of Capital Stock And Warrants
ProceedsFromIssuanceOfCapitalStockAndWarrants
6874000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
13915000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
836000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-362948000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-45055000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32899000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10643000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1291000
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2410000
CY2020 us-gaap Revenues
Revenues
1291000
CY2019 us-gaap Revenues
Revenues
2410000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33637000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14106000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50992000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12541000
CY2020 us-gaap Legal Fees
LegalFees
3267000
CY2019 us-gaap Legal Fees
LegalFees
3742000
CY2020 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
87896000
CY2019 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
30389000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-86605000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-27979000
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-435351000
CY2019 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
11828000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1582000
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1941000
CY2020 us-gaap Interest Expense
InterestExpense
8544000
CY2019 us-gaap Interest Expense
InterestExpense
2975000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
2261000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
255000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-443216000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7167000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-529821000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-20812000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
1984000
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
164000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-531805000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20976000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
725129
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
564188
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-48131000
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2019 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
4073000
CY2019 nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
2220000
CY2019 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
1759000
CY2019 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
9173000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1819000
CY2019 nwbo Adjustments To Additional Paid In Capital Beneficial Conversion Feature Of Series A Convertible Preferred Stock
AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOfSeriesAConvertiblePreferredStock
68000
CY2019 nwbo Reclass Between Shares Payable And Additional Paid In Capital
ReclassBetweenSharesPayableAndAdditionalPaidInCapital
138000
CY2020 nwbo Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise
9478000
CY2020 nwbo Adjustments To Additional Paid In Capital Beneficial Conversion Feature Of Series A Convertible Preferred Stock
AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOfSeriesAConvertiblePreferredStock
44000
CY2020 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
1133000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
52209000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-529821000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1984000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-362948000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-529821000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-20812000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
87000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
21000
CY2020 nwbo Amortization Of Debt Discount
AmortizationOfDebtDiscount
3013000
CY2019 nwbo Amortization Of Debt Discount
AmortizationOfDebtDiscount
1430000
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-435351000
CY2019 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
11828000
CY2020 nwbo Change In Fair Value Of Contingent Liability
ChangeInFairValueOfContingentLiability
-913000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1582000
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1941000
CY2020 nwbo Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
338000
CY2019 nwbo Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
-322000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-164000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-45055000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
600000
CY2020 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
16491000
CY2020 nwbo Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest
StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest
19649000
CY2020 nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
13915000
CY2020 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
22701000
CY2019 nwbo Stock Based Compensation Related To Warrants Modification
StockBasedCompensationRelatedToWarrantsModification
3000
CY2020 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
52209000
CY2019 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1819000
CY2020 nwbo Noncash Interest Expense
NoncashInterestExpense
4270000
CY2020 us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
497763000
CY2019 us-gaap Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-6936000
CY2020 nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
2350000
CY2019 nwbo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
1226000
CY2020 nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
31000
CY2019 nwbo Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
11000
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1702000
CY2019 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
30000
CY2020 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
431000
CY2019 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-3230000
CY2020 nwbo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
213000
CY2019 nwbo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
326000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32093000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31859000
CY2020 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
6610000
CY2019 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
360000
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2220000
CY2020 nwbo Proceeds From Warrant Modification
ProceedsFromWarrantModification
4000
CY2019 nwbo Proceeds From Warrant Modification
ProceedsFromWarrantModification
7000
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
8557000
CY2019 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
7000000
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
5115000
CY2020 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
315000
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1556000
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
420000
CY2020 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
379000
CY2019 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
329000
CY2020 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
89000
CY2019 nwbo Repayment Of Convertible Notes Payable To Related Party
RepaymentOfConvertibleNotesPayableToRelatedParty
5400000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52696000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9952000
CY2020 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-2850000
CY2019 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
415000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9611000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21852000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
372000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22224000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9983000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
372000
CY2020 us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
220000
CY2020 nwbo Stock Issued During Period Value For Warrant Cashless Exercise
StockIssuedDuringPeriodValueForWarrantCashlessExercise
7000
CY2020 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
22701000
CY2019 nwbo Adjustments To Additional Paid In Capital Reclassification
AdjustmentsToAdditionalPaidInCapitalReclassification
1759000
CY2020 nwbo Adjustment To Additional Paid In Capital Reclassification Of Cashless Warrants Exercised
AdjustmentToAdditionalPaidInCapitalReclassificationOfCashlessWarrantsExercised
9478000
CY2020 nwbo Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received
IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived
8230000
CY2019 nwbo Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest Received
IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterestReceived
7313000
CY2020 nwbo Offering Cost Related To Warrant Liability
OfferingCostRelatedToWarrantLiability
4876000
CY2019 nwbo Offering Cost Related To Warrant Liability
OfferingCostRelatedToWarrantLiability
2693000
CY2019 nwbo Deferred Offering Cost
DeferredOfferingCost
108000
CY2020 nwbo Warrants Issued Associated With Convertible Notes Payable
WarrantsIssuedAssociatedWithConvertibleNotesPayable
153000
CY2020 nwbo Warrants Issued In Connection With Debt Modification
WarrantsIssuedInConnectionWithDebtModification
395000
CY2020 nwbo Warrant Modification In Connection With Debt Amendment
WarrantModificationInConnectionWithDebtAmendment
91000
CY2020 nwbo Adjustments To Additional Paid In Capital Beneficial Conversion Feature Of Series A Convertible Preferred Stock
AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOfSeriesAConvertiblePreferredStock
44000
CY2019 nwbo Adjustments To Additional Paid In Capital Beneficial Conversion Feature Of Series A Convertible Preferred Stock
AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureOfSeriesAConvertiblePreferredStock
68000
CY2019 nwbo Reclass Between Shares Payable And Additional Paid In Capital
ReclassBetweenSharesPayableAndAdditionalPaidInCapital
138000
CY2020 nwbo Capital Expenditures Included In Accounts Payable
CapitalExpendituresIncludedInAccountsPayable
1088000
CY2019 nwbo Capital Expenditures Included In Accounts Payable
CapitalExpendituresIncludedInAccountsPayable
947000
CY2019 nwbo Conversion Of Outstanding Accounts Payables To Note Payable And Contingent Payable
ConversionOfOutstandingAccountsPayablesToNotePayableAndContingentPayable
8560000
CY2019 nwbo Issuance Of Common Shares In With Connection Settlement Agreement
IssuanceOfCommonSharesInWithConnectionSettlementAgreement
12000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-529800000
CY2020 nwbo Net Cash Loss
NetCashLoss
32000000
CY2020 nwbo Net Non Cash Loss
NetNonCashLoss
497800000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32100000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On an ongoing basis, the Company evaluates its estimates and judgments, including valuing equity securities in share-based payment arrangements, estimating the fair value of financial instruments recorded as derivative liabilities, useful lives of depreciable assets and whether impairment charges may apply. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic ("COVID-19") and the COVID-19 control responses.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution, which at times may exceed the Federal depository insurance coverage (“FDIC”) of $250,000. As of December 31, 2020, of the total $10 million in cash and cash equivalents, $0.6 million was held by foreign subsidiaries. The Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2020Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
10000000
CY2020Q4 nwbo Cash And Cash Equivalents Held By Foreign Subsidiaries
CashAndCashEquivalentsHeldByForeignSubsidiaries
600000
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020 us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Embedded Conversion Features</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company evaluates embedded conversion features within convertible debt instruments to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in the Statement of Operations. If the conversion feature does not require recognition of a bifurcated derivative, the convertible debt instrument is evaluated for consideration of any beneficial conversion feature (“BCF”) requiring separate recognition. When the Company record a BCF, the intrinsic value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid-in capital) and amortized to interest expense over the life of the debt.</p>
CY2020 us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Derivative Financial Instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expense), on a net basis in the Consolidated Statements of Operations and Comprehensive Loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Contingent payable derivative liability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company entered into a settlement agreement with Cognate BioServices, resolving past matters and providing for the restart of DCVax®-Direct Production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of this overall settlement, the Company also provided a contingent note payable (the “Contingent Payable Derivative”) of $10 million, which is only payable upon the Company’s first financing after DCVax product approval in or outside the U.S. If such product approval has not been obtained by the seventh anniversary of the agreement, such Contingent Payable Derivative will expire without becoming payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On a quarterly basis, management makes estimates for key performance milestones and uses the expected dates as the inputs for valuation. The fair value of the Contingent Payable Derivative has been estimated using Monte Carlo simulation, which are valued using Level 3 valuation inputs.</p>
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
354972000
CY2020Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
2507000
CY2020Q4 nwbo Contingent Payable Derivative Liability
ContingentPayableDerivativeLiability
8275000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
365754000
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
20213000
CY2019Q4 nwbo Contingent Payable Derivative Liability
ContingentPayableDerivativeLiability
7261000
CY2019Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
27474000
CY2018Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
30352000
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
6602000
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
4110000
CY2019 nwbo Fairvalue Measurement With Unobservable Inputs Reconciliation Recurring Basis Extinguishment Of Derivative Liabilities
FairvalueMeasurementWithUnobservableInputsReconciliationRecurringBasisExtinguishmentOfDerivativeLiabilities
-3000
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Sales
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
1759000
CY2019 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-11828000
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
27474000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
18864000
CY2020 nwbo Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification For Warrants Exercised For Cash
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationForWarrantsExercisedForCash
110471000
CY2020 nwbo Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Related To Repayment Of Debt
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRelatedToRepaymentOfDebt
-8271000
CY2020 nwbo Bifurcated Embedded Derivative Fair Value Of Embedded Derivative Liability1
BifurcatedEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability1
2807000
CY2020 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
435351000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
365754000
CY2020Q3 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
200000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51955000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1821000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.26
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.20
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y2M12D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.98
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.86
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.01
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
17000000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
100159
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.24
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4500
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.22
CY2019 nwbo Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
P10Y4M24D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
104659
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.24
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
208525
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.37
CY2020 nwbo Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
P10Y
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
94
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.34
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
4250
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.22
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
308840
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.33
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M24D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
372219000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
223720
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.30
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
276432000
CY2020Q2 nwbo Share Based Compensation Arrangement By Share Based Payment Award Number Of Stock Options Agreed Not To Be Exercised By Holder
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfStockOptionsAgreedNotToBeExercisedByHolder
39200000
CY2020Q2 nwbo Share Based Compensation Arrangement By Share Based Payment Award Period During Which Stock Options Agreed Not To Be Exercised By Holder
ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodDuringWhichStockOptionsAgreedNotToBeExercisedByHolder
P6M
CY2020Q2 nwbo Share Based Compensation Arrangement By Share Based Payment Award Stock Option Extended Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionExtendedContractualTerm
P6M
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
78000000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1750000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3000000
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.22
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
300000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1040000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
281000
CY2020 us-gaap Depreciation
Depreciation
87000
CY2019 us-gaap Depreciation
Depreciation
21000
CY2020Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
13751000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1484000
CY2020Q4 nwbo Fair Value Of Embedded Conversion Option
FairValueOfEmbeddedConversionOption
-2507000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
14774000
CY2019Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
13411000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
688000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
12723000
CY2019Q4 us-gaap Notes Payable
NotesPayable
135000
CY2020Q4 us-gaap Notes Payable
NotesPayable
135000
CY2019Q2 us-gaap Repayments Of Debt
RepaymentsOfDebt
1200000
CY2020 us-gaap Interest Expense Other
InterestExpenseOther
10000
CY2019 us-gaap Interest Expense Other
InterestExpenseOther
11000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
8544000
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
2975000
CY2020Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
13751000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
643210000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
466749000
CY2019 nwbo Number Of Warrants Warrants Exercised For Cash
NumberOfWarrantsWarrantsExercisedForCash
9532
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8500000
CY2020Q4 nwbo Class Of Warrant Or Right Agreed To Be Suspended
ClassOfWarrantOrRightAgreedToBeSuspended
14600000
CY2020Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
5300000
CY2020Q4 nwbo Shares Issued During Period Shares Upon Exercise Of Warrants
SharesIssuedDuringPeriodSharesUponExerciseOfWarrants
47500000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
13900000
CY2020 nwbo Number Of Common Stock Issued Cashless Exercise
NumberOfCommonStockIssuedCashlessExercise
7100000
CY2020 nwbo Weighted Average Exercise Price Warrants Cashless Exercise
WeightedAverageExercisePriceWarrantsCashlessExercise
0.22
CY2019Q4 nwbo Common Stock Shares Issued Upon Existing Loan Conversion
CommonStockSharesIssuedUponExistingLoanConversion
1300000
CY2019Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
5400000
CY2019Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
800000
CY2018Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
65000
CY2018Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.10
CY2020 us-gaap Contractual Interest Expense On Prepetition Liabilities Not Recognized In Statement Of Operations
ContractualInterestExpenseOnPrepetitionLiabilitiesNotRecognizedInStatementOfOperations
20000
CY2019 us-gaap Contractual Interest Expense On Prepetition Liabilities Not Recognized In Statement Of Operations
ContractualInterestExpenseOnPrepetitionLiabilitiesNotRecognizedInStatementOfOperations
366000
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
122000
CY2019 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
CY2020 nwbo Interest Expense Related To Forbearance Of Debt
InterestExpenseRelatedToForbearanceOfDebt
4270000
CY2019 nwbo Interest Expense Related To Forbearance Of Debt
InterestExpenseRelatedToForbearanceOfDebt
0
CY2020 us-gaap Interest And Debt Expense
InterestAndDebtExpense
4412000
CY2019 us-gaap Interest And Debt Expense
InterestAndDebtExpense
366000
CY2019 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
6900000
CY2019 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
300000
CY2019Q4 nwbo Shares Issued During Period Shares Upon Exercise Of Warrants
SharesIssuedDuringPeriodSharesUponExerciseOfWarrants
9500000
CY2019 nwbo Value Of Warrants Exercised For Cash
ValueOfWarrantsExercisedForCash
2200000
CY2019 nwbo Issuance Of Common Shares In Settlement Agreement In Shares
IssuanceOfCommonSharesInSettlementAgreementInShares
12000000
CY2019 nwbo Issuance Of Common Shares In Settlement Agreement
IssuanceOfCommonSharesInSettlementAgreement
52000000
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
372153
CY2018Q4 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.29
CY2019 nwbo Weighted Average Exercise Price Exercised For Cash
WeightedAverageExercisePriceExercisedForCash
0.23
CY2019 nwbo Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
11215
CY2018 nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P1Y11M19D
CY2019 nwbo Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
8067
CY2019 nwbo Class Of Warrant Or Right Granted Weighted Average Exercise Price
ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice
0.23
CY2019 nwbo Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
0.0062
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
359473
CY2019Q4 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.27
CY2019 nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P1Y5M1D
CY2020 nwbo Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
88658
CY2020 nwbo Class Of Warrant Or Right Granted Weighted Average Exercise Price
ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice
0.22
CY2020 nwbo Class Of Warrant Contingently Issuable Warrants
ClassOfWarrantContingentlyIssuableWarrants
2774
CY2020 nwbo Class Of Warrant Or Right Granted Weighted Average Contingently Issuable Warrants
ClassOfWarrantOrRightGrantedWeightedAverageContingentlyIssuableWarrants
1.48
CY2020 nwbo Number Of Warrants Warrants Exercised For Cash
NumberOfWarrantsWarrantsExercisedForCash
47511
CY2020 nwbo Weighted Average Exercise Price Exercised For Cash
WeightedAverageExercisePriceExercisedForCash
0.29
CY2020 nwbo Number Of Warrants Warrants Cashless Exercise
NumberOfWarrantsWarrantsCashlessExercise
8631
CY2020 nwbo Weighted Average Exercise Price Warrants Cashless Exercise
WeightedAverageExercisePriceWarrantsCashlessExercise
0.22
CY2020 nwbo Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
63010
CY2020 nwbo Class Of Warrant Or Right Expired Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice
0.0032
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
331753
CY2020Q4 nwbo Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.28
CY2020 nwbo Class Of Warrant Or Right Outstanding Remaining Contractual Term
ClassOfWarrantOrRightOutstandingRemainingContractualTerm
P1Y7M9D
CY2020Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
2800000
CY2020Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
272800000
CY2020Q2 nwbo Class Of Warrant Or Right Percentage Of Warrants Issued On Conversion
ClassOfWarrantOrRightPercentageOfWarrantsIssuedOnConversion
0.175
CY2020Q2 nwbo Class Of Warrant Or Right Suspended
ClassOfWarrantOrRightSuspended
81000000
CY2020Q2 nwbo Class Of Warrant Or Right Agreed To Be Suspended
ClassOfWarrantOrRightAgreedToBeSuspended
14200000
CY2020Q2 nwbo Class Of Warrant Or Right Agreed To Be Suspended And Unexercisable
ClassOfWarrantOrRightAgreedToBeSuspendedAndUnexercisable
90000000
CY2020Q4 nwbo Class Of Warrant Or Right Agreed To Be Suspended And Unexercisable
ClassOfWarrantOrRightAgreedToBeSuspendedAndUnexercisable
60000000
CY2020Q4 nwbo Class Of Warrant Or Right Suspended
ClassOfWarrantOrRightSuspended
29000000
CY2020Q4 nwbo Class Of Warrant Or Right Agreed To Be Suspended And Unexercisable
ClassOfWarrantOrRightAgreedToBeSuspendedAndUnexercisable
60000000
CY2020Q4 nwbo Class Of Warrant Or Right Suspended
ClassOfWarrantOrRightSuspended
29000000
CY2020Q4 nwbo Class Of Warrant Or Right Suspended
ClassOfWarrantOrRightSuspended
29000000
CY2020Q4 nwbo Class Of Warrant Or Right Extended In Suspension
ClassOfWarrantOrRightExtendedInSuspension
157000000
CY2020Q4 nwbo Class Of Warrant Or Right Suspended And Unexercisable
ClassOfWarrantOrRightSuspendedAndUnexercisable
171000000
CY2020Q4 nwbo Class Of Warrant Or Right Extended In Suspension
ClassOfWarrantOrRightExtendedInSuspension
157000000
CY2020Q4 nwbo Class Of Warrant Or Right Suspended
ClassOfWarrantOrRightSuspended
274000000
CY2020Q4 nwbo Class Of Warrant Or Right Suspended
ClassOfWarrantOrRightSuspended
183000000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4300000
CY2020Q4 us-gaap Lease Practical Expedient Lessor Single Lease Component
LeasePracticalExpedientLessorSingleLeaseComponent
true
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5100000
CY2020Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P20Y
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
940000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
44000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
65000
CY2020 us-gaap Lease Cost
LeaseCost
1049000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
993000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
854000
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
131000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
15000
CY2019 us-gaap Lease Cost
LeaseCost
1000000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
244000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
728000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
644000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
644000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
644000
CY2020Q4 nwbo Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
8990000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11650000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6567000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5083000
CY2020 nwbo Original Term Of Agreement
OriginalTermOfAgreement
P8M
CY2020 nwbo Extended Term Of Agreement
ExtendedTermOfAgreement
P12M
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
185308000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
176140000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
18580000
CY2019Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
16983000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
22997000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
14565000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
226885000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
207688000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
226885000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
207688000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
654500000
CY2020Q4 nwbo Deferred Tax Assets Tax Credit Carry Forward Unused Research And Development
DeferredTaxAssetsTaxCreditCarryForwardUnusedResearchAndDevelopment
547000000.0
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
18600000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
30000000.0
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.011
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.089
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.173
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.122
CY2020 nwbo Effective Income Tax Rate Reconciliation Expiration Of Net Operating Losses
EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLosses
0.015
CY2019 nwbo Effective Income Tax Rate Reconciliation Expiration Of Net Operating Losses
EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLosses
0.079
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.023
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.003
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.030
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.035
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.345
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-15539000
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-5183000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-4327000
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1421000
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
670000
CY2019 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-404000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-19196000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-7008000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019Q4 nwbo Constructions In Progress Net
ConstructionsInProgressNet
1685000
CY2019Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
7443000
CY2019Q4 us-gaap Assets
Assets
10643000
CY2019Q4 nwbo Accounts Payable And Accrued Liabilities Related Parties Current
AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent
3844000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
44196000
CY2019Q4 us-gaap Liabilities
Liabilities
55698000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-841395000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-45055000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10643000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14106000
CY2019 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
30389000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-27979000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-20812000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20976000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-20812000
CY2019 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-3230000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31859000
CY2019 nwbo Capital Expenditures Included In Accounts Payable And Accrued Expenses To Related Parties And Affiliates
CapitalExpendituresIncludedInAccountsPayableAndAccruedExpensesToRelatedPartiesAndAffiliates
947000

Files In Submission

Name View Source Status
0001104659-21-044832-index-headers.html Edgar Link pending
0001104659-21-044832-index.html Edgar Link pending
0001104659-21-044832.txt Edgar Link pending
0001104659-21-044832-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nwbo-20201231.xsd Edgar Link pending
nwbo-20201231x10k.htm Edgar Link pending
nwbo-20201231x10k_htm.xml Edgar Link completed
nwbo-20201231xex10d81.htm Edgar Link pending
nwbo-20201231xex10d82.htm Edgar Link pending
nwbo-20201231xex10d83.htm Edgar Link pending
nwbo-20201231xex10d83001.jpg Edgar Link pending
nwbo-20201231xex10d83002.jpg Edgar Link pending
nwbo-20201231xex10d83003.jpg Edgar Link pending
nwbo-20201231xex10d85.htm Edgar Link pending
nwbo-20201231xex21d1.htm Edgar Link pending
nwbo-20201231xex23d1.htm Edgar Link pending
nwbo-20201231xex31d1.htm Edgar Link pending
nwbo-20201231xex32d1.htm Edgar Link pending
nwbo-20201231xex4d1.htm Edgar Link pending
nwbo-20201231_cal.xml Edgar Link unprocessable
nwbo-20201231_def.xml Edgar Link unprocessable
nwbo-20201231_lab.xml Edgar Link unprocessable
nwbo-20201231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending